This is in accordance with different studies, which uncovered that miR-203 directly targets its upstream regulator ZEB2, suppressing EMT in lung adenocarcinoma [69], nasopharyngeal carcinoma [57], prostate cancer [70], and clear cell renal cell carcinoma [71]. The gene discussed is ZEB2; the disease is nasopharyngeal carcinoma.